Pharmapack 2025 Shows Industry's Green Transformation Challenges

The pharmaceutical industry is facing a sustainability revolution, with new data from the Pharmapack 2025 Strategic Insights & Research survey highlighting both progress and persistent obstacles across the sector.

The business case for sustainability

Most organisations now acknowledge the business case for sustainability, with 57% identifying competitive advantage as a key benefit and 45% recognising enhanced reputation and stakeholder trust as valuable outcomes. Despite this growing consensus, a small but notable 7% of respondents still see limited tangible value in sustainability initiatives, suggesting pockets of resistance remain within the industry.

The integration of sustainability principles shows varied progress across pharmaceutical companies. While 30% of respondents report having fully embedded sustainability into their organisational mission, a significant 70% consider it important to their roles without full integration. This suggests that while sustainability awareness is widespread, comprehensive implementation remains a work in progress for many companies.

Current practices and emerging barriers

Current sustainability tracking efforts focus primarily on carbon footprint measurements, recyclable materials usage, and sustainability questionnaires. However, the industry is witnessing a notable shift towards more sophisticated approaches, including decarbonising raw materials and implementing energy consumption reduction strategies. This evolution reflects growing maturity in the sector's approach to environmental impact.

The path to sustainability is not without significant hurdles. Resource constraints emerged as the dominant barrier, cited by 76% of respondents, followed closely by the lack of standardised data-sharing formats (73%) and insufficient regulatory guidance (70%). These challenges create a complex landscape for companies attempting to advance their sustainability agendas.

Regulatory landscape and industry readiness

Regulatory pressures continue to mount, particularly around packaging and waste management, with requirements for 100% recyclable packaging by 2030 looming on the horizon. The industry's response to these regulations appears mixed – while 45% view sustainability regulations as potential drivers of innovation and opportunity, the overall sentiment suggests a conservative approach and general unpreparedness for coming changes.

Understanding regulatory scope was identified as a key challenge by 43% of respondents, with managing supply chain data collection (36%) and high compliance costs (29%) also presenting significant obstacles. Looking ahead, new data requirements will increasingly be driven by the Corporate Sustainability Reporting Directive (CSRD), intensifying regulatory pressure, and evolving customer expectations.

Building knowledge and collaborative solutions

For knowledge building and improvement, respondents placed high value on case studies and best practices (76%), regulatory updates (74%), and sustainability performance tools (68%). Perhaps most tellingly, the Sustainability Collective highlighted a fundamental structural issue: pharmaceutical organisations aren't currently configured to effectively generate and share sustainability data, creating an industry-wide challenge that will require collaborative solutions rather than individual company efforts.

As the industry moves toward 2025, these findings suggest that while the pharmaceutical sector recognises the importance of sustainability, significant structural and practical challenges remain before green practices become truly embedded in the industry's DNA.

Click the image below to see the infographic in more detail.